atherosclerotic cardiovascular disease
Cardiovascular · 2017–2022
2decisions
2medicines
2carried consumer input
15individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| evolocumab Extension of Section 85 (Authority Required) PBS listings for treatment of atherosclerotic cardiovascular disease (ASCVD) with high risk factors (including… | Jul 2022 | Recommended with restriction | 2 individuals |
| alirocumab Treatment of heterozygous familial hypercholesterolaemia (HeFH) and clinical atherosclerotic cardiovascular disease (ASCVD) in patients with inadequate control… | Nov 2017 | Not recommended | 13 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.